TABLE 3

Changes in OGTT-derived measures of β-cell function (insulinogenic index) and insulin sensitivity (1/fasting insulin) for the 4-year completer and monotherapy failure cohorts from baseline to 0.5 years and rates of change among means from 0.5 to 4 years based on a longitudinal model adjusted for baseline factors

Variable4-Year completer cohort4-Year monotherapy failure cohort
RosiglitazoneMetforminGlyburideRosiglitazoneMetforminGlyburide
Insulinogenic index (pmol/L per mmol/L)
 n69167151293128215
 Mean %change from 0 to 0.5 years0.2 (−4.5, 5.2)5.2 (0.2, 10.5)4.2 (−1.5, 10.1)−8.0 (−21.5, 7.9)8.3 (−5.3, 24.0)13.5* (2.2, 25.9)
 Rate of change from 0.5 to 4 years   (% per year)−5.3 (−6.6, −4.0)−6.6 (−7.9, −5.4)−10.6* (−12.0, −9.2)−20.0 (−27.2, −12.2)−16.9 (−22.9, −10.6)−19.9 (−25.1, −14.4)
1/Fasting insulin (pmol/L−1 × 10−3)
 n756730555108153244
 Mean %change from 0 to 0.5 years26.1 (22.5, 29.8)14.5* (11.2, 17.9)−5.2* (−8.3, −1.9)20.1 (11.3, 29.6)3.6* (−2.8, 10.4)−13.5* (−17.8, −9.0)
 Rate of change from 0.5 to 4 years (% per year)6.6 (5.8, 7.4)6.0 (5.2, 6.8)5.4* (4.4, 6.3)4.5 (0.0, 9.3)5.9 (2.8, 9.2)4.6 (1.3, 8.0)
  • For the log-transformed insulinogenic index and reciprocal fasting insulin, results presented as a percent change from baseline and mean rates of change (percent per year) ± 95% confidence limits. Changes from baseline, or rates of change, for which the 95% confidence limits do not bracket zero are statistically significantly different at the 0.05 level, without adjustment for multiple tests of significance.

  • *P < 0.05 for metformin or glyburide vs. rosiglitazone.